Activities of Kateřina KONEČNÁ related to 2019/2816(RSP)
Institutional motions (1)
MOTION FOR A RESOLUTION on a strategic approach to pharmaceuticals in the environment
Amendments (24)
Amendment 14 #
Citation 12 a (new)
- having regard to the Council conclusions of 24 June 2019 on the next steps towards making the EU a best practice region in combatting antimicrobial resistance,
Amendment 18 #
Citation 17 a (new)
- having regard to the Commission Communication of the 11 December 2019 entitled ‘European Green Deal’ (COM(2019) 640),
Amendment 26 #
Citation 22 a (new)
- having regard to the OECD study of November 2019 Pharmaceutical Residues in Freshwater - Hazards and Policy Responses,
Amendment 37 #
Recital B
B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas environmental concentrations are likely to increase as the population ages and grows, and the impacts of climate change will increasingly and adversely affect both the quantity and the quality of water resources; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;
Amendment 44 #
Recital D
D. whereas the excessive and incorrect use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health; whereas intensive livestock farming, where large numbers of animals are kept in close proximity to each other, leads to the excessive use of veterinary medicines including antibiotics;
Amendment 52 #
Recital D a (new)
D a. whereas the veterinary antibiotics (VAs) are used in large amounts for therapeutic and prophylactic purposes in addition to their application as growth promoters;
Amendment 61 #
Recital G
G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment; such as the impact on drinking water sources;
Amendment 82 #
Paragraph 4
4. Recalls that any future initiatives in the field of the environmental impact of pharmaceuticals should be science andbased on the precautionary principle, target driven, as well asnd technology neutral, making sure that safety and efficacy still remain key priority features for access for patients to pharmaceutical treatments;
Amendment 95 #
Paragraph 7
7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plants currently cannot effectively filter out all pharmaceutical products, due to the intrinsically different chemical properties of the relevant substances;
Amendment 111 #
Paragraph 9
9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse; asks that regulation for other compartments such as soils be implemented as well;
Amendment 116 #
Paragraph 10
10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants in accordance with the control at source principle, and additional hot spots such as certain waste water treatment plants;
Amendment 119 #
Paragraph 10
10. Asks for a special focus to be put on emission hot spots, such as hospitals and, pharmaceutical production plants and intensive stockbreeding areas;
Amendment 142 #
Paragraph 13
13. Calls on the Member States and on the Commission to promote awareness- raising campaigns among veterinaries and physicians on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients and stockbreeders with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;
Amendment 147 #
Paragraph 14
14. Highlights the importance of the design, development and manufacturing phases to minimise the environmental impact of pharmaceuticals; has the opinion that the Good Manufacturing Practice (GMP) legislation should be revised to include requirements for environmental protection;
Amendment 189 #
Paragraph 22 a (new)
22 a. Calls on the Commission to include compulsory environmental criteria in the Good Manufacturing Practice (GMP) framework to give EU inspectors the ability to control manufacturing discharges at overseas pharmaceutical factories supplying the EU market;
Amendment 198 #
Paragraph 26
26. Stresses that measures must be based on scientific evidencthe precautionary principle and calls on all relevant players to ensure that actions taken do not jeopardise access to safe and effective pharmaceutical treatments for human patients and animals; in this regard, supports the Commission’s intention to reduce waste by allowing that medicines be dispensed in quantities better matching needs, including by optimising the package size, and to explore the possibility to extend expiry dates for medicines to avoid that medicines that can still be safely used are unnecessarily thrown away;
Amendment 199 #
Paragraph 26 a (new)
26 a. Calls for an update of the requirements with regard to the environmental risk assessment to ensure a proper assessment of mixture effects and take into account the risk for the development of antimicrobial resistance in the environment;
Amendment 213 #
Paragraph 29
29. Considers that pharmaceutical production plants should pre-treat their wastewater; request in this context that the relevant authorities set monitoring requirements to the industry as well as stricter limits to the concentrations of pharmaceuticals in the wastewater ending up to the municipal WWTPs;
Amendment 228 #
Paragraph 31 a (new)
31 a. Recalls that the Commission is due to evaluate the feasibility of setting up an EU-wide active substance-based review system by 28 January 2022 and calls on the Commission to make a legislative proposal to adopt such a review system;
Amendment 238 #
Paragraph 33
33. Calls on the Commission to address the possible impact of pharmaceuticals on the watchlist pursuant to the Water Framework Directive and to assess whether the list should be updated; calls on the Commission to propose a soil framework directive, focusing in particular on the concentration of antibiotics in the soil;
Amendment 242 #
Paragraph 34
34. Highlights that comprehensive monitoring of antibiotics has been developed in farming; calls on the Commission to also develop a monitoring system in relation to human antibiotics; calls on the Commission to propose a pharmaceuticals monitoring programme, focusing in particular on the concentration of antibiotics in the soil;
Amendment 244 #
Paragraph 35
35. Emphasises the need to support further research, particularly under the next multi-annual financial framework, on the direct impact on human health of exposure to pharmaceuticals and their residues in the environment and on better understanding how pharmaceuticals enter and persist in the environment and the environmental fate of pharmaceuticals;
Amendment 248 #
Paragraph 35 a (new)
35 a. Calls on the Commission to include pharmaceuticals that pose a significant risk to the environment in the list of priority substances under the Water Framework Directive and set environmental quality standards and concentration limits under the Environmental Quality Standards (EQS) Directive;
Amendment 254 #
Paragraph 37
37. Recalls that pharmaceutical environmental information such as the impact on water, environmental behaviour, degradability and possible cocktail effects plays a key role for risk management and that this type of information should be transparent and made available to relevant stakeholders;